Renovaro Inc. (NASDAQ:RENB) Major Shareholder Anderson Wittekind William Sells 50,000 Shares of Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 50,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1.58, for a total transaction of $79,000.00. Following the transaction, the insider now owns 1,263,499 shares in the company, valued at approximately $1,996,328.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Renovaro Price Performance

Shares of RENB opened at $1.45 on Wednesday. Renovaro Inc. has a one year low of $0.39 and a one year high of $5.25. The company has a 50-day simple moving average of $1.56 and a two-hundred day simple moving average of $2.70. The firm has a market capitalization of $213.89 million, a PE ratio of -1.86 and a beta of 0.44.

Renovaro (NASDAQ:RENB) last released its earnings results on Wednesday, May 15th. The company reported ($0.08) EPS for the quarter.

Hedge Funds Weigh In On Renovaro

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Renovaro in the 1st quarter worth about $46,000. Tidal Investments LLC bought a new stake in Renovaro during the first quarter worth about $98,000. Finally, Vanguard Group Inc. grew its holdings in Renovaro by 904.0% in the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after purchasing an additional 3,526,565 shares during the period. Hedge funds and other institutional investors own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.